| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Second Department of Internal Medicine (Y.T., K.F., H.M.), Department of Health Sciences (Y.T.), School of Medicine, Kanazawa University, Kanazawa 920, Japan; and Third Department of Internal Medicine (S.I., I.M.), Fukui Medical School, Fukui 91011, Japan
Address all correspondence and requests for reprints to: Yoshiyu Takeda, M.D., Second Department of Internal Medicine, School of Medicine, Kanazawa University, 131 Takara-machi, Kanazawa 920, Japan. E-mail: takeday{at}mhs.mp.kanazawa-u.ac.jp
Idiopathic hyperaldosteronism (IHA) is characterized by hypertension with excessive production of aldosterone, potassium loss, and suppression of the renin-angiotensin system. We compared activity of aldosterone synthase and expression of CYP11B2 messenger RNA (mRNA) in mononuclear leukocytes (MNL) from patients with IHA to findings in leukocytes from patients with aldosterone-producing adenoma and normal controls. Aldosterone synthase activity was estimated from conversion of [14C]deoxycorticosterone to [14C]aldosterone. Levels of CYP11B2 mRNA were determined by competitive PCR. In the same subjects, we sought the chimeric CYP11B1/CYP11B2 that is candidate gene for glucocorticoid-remediable hyperaldosteronism. Southern blot analysis and a long PCR method were used to detect the chimeric gene. Direct sequencing of the CYP11B2 also was performed. No chimeric genes or mutations in the coding region of the CYP11B2 were found in genomic DNA from these patients. However, both aldosterone synthase activity and CYP11B2 mRNA expression were greater in mononuclear leukocytes of patients with IHA than those of patients with aldosterone-producing adenoma or controls. These results suggest that regulatory factors of the CYP11B2 gene, e.g. unidentified aldosterone-stimulating substances or abnormalities in the promoter region of the CYP11B2 gene in patients with IHA resulting in oversecretion, may cause overexpression of mRNA of CYP11B2.
This article has been cited by other articles:
![]() |
E. Ritz How Little Aldosterone is Able to Raise Blood Pressure? Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 703 - 710. [Full Text] [PDF] |
||||
![]() |
G. Siest, E. Jeannesson, J.-B. Marteau, A. Samara, B. Marie, M. Pfister, and S. Visvikis-Siest Transcription Factor and Drug-Metabolizing Enzyme Gene Expression in Lymphocytes from Healthy Human Subjects Drug Metab. Dispos., January 1, 2008; 36(1): 182 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Makhanova, J. Hagaman, H.-S. Kim, and O. Smithies Salt-Sensitive Blood Pressure in Mice With Increased Expression of Aldosterone Synthase Hypertension, January 1, 2008; 51(1): 134 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J Casal, V. J P Sinclair, A. M Capponi, J. Nicod, U. Huynh-Do, and P. Ferrari A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity. J. Mol. Endocrinol., August 1, 2006; 37(1): 71 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kurihara, H. Shibata, S. Kobayashi, N. Suda, Y. Ikeda, K. Yokota, A. Murai, I. Saito, W. E. Rainey, and T. Saruta Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription J. Biol. Chem., February 25, 2005; 280(8): 6721 - 6730. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ganapathipillai, G. Laval, I. S. Hoffmann, A. M. Castejon, J. Nicod, B. Dick, F. J. Frey, B. M. Frey, L. X. Cubeddu, and P. Ferrari CYP11B2-CYP11B1 Haplotypes Associated with Decreased 11{beta}-Hydroxylase Activity J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1220 - 1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nicod, D. Bruhin, L. Auer, B. Vogt, F. J. Frey, and P. Ferrari A Biallelic Gene Polymorphism of CYP11B2 Predicts Increased Aldosterone to Renin Ratio in Selected Hypertensive Patients J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2495 - 2500. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. O. Lim, T. M. Macdonald, C. Holloway, E. Friel, N. H. Anderson, E. Dow, R. T. Jung, E. Davies, R. Fraser, and J. M. C. Connell Variation at the Aldosterone Synthase (CYP11B2) Locus Contributes to Hypertension in Subjects with a Raised Aldosterone-to-Renin Ratio J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4398 - 4402. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mulatero, F. Rabbia, and F. Veglio Paraneoplastic Hyperaldosteronism Associated with Non-Hodgkin's Lymphoma N. Engl. J. Med., May 17, 2001; 344(20): 1558 - 1559. [Full Text] [PDF] |
||||
![]() |
P. Mulatero, D. Schiavone, F. Fallo, F. Rabbia, C. Pilon, L. Chiandussi, L. Pascoe, and F. Veglio CYP11B2 Gene Polymorphisms in Idiopathic Hyperaldosteronism Hypertension, March 1, 2000; 35(3): 694 - 698. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |